Jim Cramer -- I Agree With the Analysts on Gap, Allergan

Cramer agrees with analysts' bullish calls on Gap and Allergan.
By Bret Kenwell ,

On Monday's CNBC "Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, looked at several analyst reports.

The first was a research report from the analysts at Wells Fargo, who think the situation at retailer Gap (GPS) - Get Report is improving. Its shares are currently up 3%.

"The product looks great for the first time in so many years," Cramer said. "I cannot believe it." He reminisced about a recent trip to Rome where he visited a Gap store, which was "jammed" and had a great product lineup.

Next to be reviewed was an outperform initiation on shares of Allergan (AGN) - Get Report , an Action Alerts PLUS portfolio holding. Analysts at Credit Suisse assigned a $327 price target, too, implying about 30% upside from current levels.

Investors in Allergan have been waiting and waiting for the approval of the Teva Pharmaceuticals (TEVA) - Get Report deal to go through, Cramer said. This research report reads like that deal will gain regulatory approval at any moment, he reasoned.

"I like both of these calls very, very much," Cramer concluded.

At the time of publication, Cramer's Action Alerts PLUS had a position in AGN. 

Loading ...